Hong Li
Merck & Co.
12 Papers
52 Citations
Hong Li is an academic researcher from Merck & Co.. The author has contributed to research in topics: Anacetrapib & Cholesterylester transfer protein. The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib
Cameron J. Smith,Amjad Ali,Milton L. Hammond,Hong Li,Zhijian Lu,Joann B. Napolitano,Gayle E. Taylor,Christopher F. Thompson,Matt S. Anderson,Ying Chen,Suzanne S. Eveland,Qiu Guo,Sheryl A. Hyland,Denise P. Milot,Carl P. Sparrow,Samuel D. Wright,Anne-Marie Cumiskey,Melanie Latham,Laurence B. Peterson,Ray Rosa,James V. Pivnichny,Xinchun Tong,Suoyu S. Xu,Peter J. Sinclair +23 more
TL;DR: It was found that substitution of the 4-position with a methyl group with the cis-stereochemistry relative to the 5-aryl group afforded compounds with increased cholesteryl ester transfer protein (CETP) inhibition potency and a robust in vivo effect on increasing HDL-C levels in transgenic mice expressing cynomolgus monkey CETP.
66
Patent
1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
Amjad Ali,Zhijian Lu,Peter J. Sinclair,Yi-Heng Chen,Cameron J. Smith,Hong Li +5 more
- 29 Dec 2006
TL;DR: The CETP inhibitors have three cyclic groups connected by single bonds, such as triphenyl, which are attached directly to the ring of formula I or attached at the position B.
20
Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Dongfang Meng,Patrick Andre,Thomas Bateman,Richard A. Berger,Yi-Heng Chen,Kunal Desai,Sunita V. Dewnani,Kenneth P. Ellsworth,Daming Feng,Wayne M. Geissler,Liangqin Guo,Alan Hruza,Tianying Jian,Hong Li,Joe Metzger,Dann L. Parker,Paul Reichert,Edward C. Sherer,Cameron J. Smith,Lisa M. Sonatore,Richard Tschirret-Guth,Jane Y. Wu,Jiayi Xu,Ting Zhang,Louis-Charles Campeau,Robert K. Orr,Marc Poirier,Jamie McCabe-Dunn,Kazuto Araki,Teruyuki Nishimura,Isao Sakurada,Tomokazu Hirabayashi,Harold B. Wood +32 more
TL;DR: Using structure based drug design, a novel class of potent coagulation factor IXa (FIXa) inhibitors was designed and synthesized and high selectivity over FXa inhibition was achieved.
20
Patent
Cyclic amine substituted oxazolidinone CETP inhibitor
Zhijian Lu,Yi-Heng Chen,Cameron J. Smith,Hong Li,Chris M. Thompson,Ramzi F. Sweis,Peter J. Sinclair,Florida Kallashi,Julianne A. Hunt,Samantha E. Adamson,Guizhen Dong,Debra Ondeyka,Xiaoxia Qian,Wanying Sun,Petr Vachal,Kake Zhao +15 more
- 25 Oct 2011
TL;DR: In this paper, the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are used for CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL cholesterol, and for treating or preventing atherosclerosis.
16
Patent
4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases
Raphelle Berger,Yi-Heng Chen,Guoqing Li,Joie Garfunkle,Hong Li,Shouwu Miao,Subharekha Raghavan,Smith Cameron J,John E. Stelmach,Alan Whitehead,Rui Zhang,Yong Zhang,Jianmin Fu,Gang Ji,Falong Jiang +14 more
- 20 Dec 2016
TL;DR: In this article, the authors provided compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R 1, R 2, R 4, R a, and the subscripts m, p, and q are as described herein.
8